Cargando…

Design, synthesis, in vitro anticancer evaluation, kinase inhibitory effects, and pharmacokinetic profile of new 1,3,4-triarylpyrazole derivatives possessing terminal sulfonamide moiety

The present work describes the design and synthesis of a novel series of 1,3-diaryl-4-sulfonamidoarylpyrazole derivatives 1a–q and 2a–q and their in vitro biological activities. The target compounds were evaluated for antiproliferative activity against NCI-60 cell line panel. Compounds 1c, 1g, 1k–m,...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdel-Maksoud, Mohammed S., El-Gamal, Mohammed I., Gamal El-Din, Mahmoud M., Oh, Chang Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211260/
https://www.ncbi.nlm.nih.gov/pubmed/30362383
http://dx.doi.org/10.1080/14756366.2018.1530225
_version_ 1783367298480865280
author Abdel-Maksoud, Mohammed S.
El-Gamal, Mohammed I.
Gamal El-Din, Mahmoud M.
Oh, Chang Hyun
author_facet Abdel-Maksoud, Mohammed S.
El-Gamal, Mohammed I.
Gamal El-Din, Mahmoud M.
Oh, Chang Hyun
author_sort Abdel-Maksoud, Mohammed S.
collection PubMed
description The present work describes the design and synthesis of a novel series of 1,3-diaryl-4-sulfonamidoarylpyrazole derivatives 1a–q and 2a–q and their in vitro biological activities. The target compounds were evaluated for antiproliferative activity against NCI-60 cell line panel. Compounds 1c, 1g, 1k–m, 1o, 2g, 2h, 2k–m, 2o, and 2q showed the highest mean inhibition percentages at 10 µM single-dose testing and were selected to be tested at 5-dose mode. The ICs(50) of the most potent compounds were determined over the 60 cell lines. Compound 2l exhibited the strongest activity against different cell lines with IC(50) 0.33 µM against A498 renal cancer cell line. Compound 2l was tested over a panel of 20 kinases to determine its molecular target(s), and its IC(50) values over the most sensitive kinases were defined. In vitro stability and in vivo pharmacokinetic profile of compound 2l was also investigated.
format Online
Article
Text
id pubmed-6211260
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-62112602018-11-05 Design, synthesis, in vitro anticancer evaluation, kinase inhibitory effects, and pharmacokinetic profile of new 1,3,4-triarylpyrazole derivatives possessing terminal sulfonamide moiety Abdel-Maksoud, Mohammed S. El-Gamal, Mohammed I. Gamal El-Din, Mahmoud M. Oh, Chang Hyun J Enzyme Inhib Med Chem Research Paper The present work describes the design and synthesis of a novel series of 1,3-diaryl-4-sulfonamidoarylpyrazole derivatives 1a–q and 2a–q and their in vitro biological activities. The target compounds were evaluated for antiproliferative activity against NCI-60 cell line panel. Compounds 1c, 1g, 1k–m, 1o, 2g, 2h, 2k–m, 2o, and 2q showed the highest mean inhibition percentages at 10 µM single-dose testing and were selected to be tested at 5-dose mode. The ICs(50) of the most potent compounds were determined over the 60 cell lines. Compound 2l exhibited the strongest activity against different cell lines with IC(50) 0.33 µM against A498 renal cancer cell line. Compound 2l was tested over a panel of 20 kinases to determine its molecular target(s), and its IC(50) values over the most sensitive kinases were defined. In vitro stability and in vivo pharmacokinetic profile of compound 2l was also investigated. Taylor & Francis 2018-10-26 /pmc/articles/PMC6211260/ /pubmed/30362383 http://dx.doi.org/10.1080/14756366.2018.1530225 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Abdel-Maksoud, Mohammed S.
El-Gamal, Mohammed I.
Gamal El-Din, Mahmoud M.
Oh, Chang Hyun
Design, synthesis, in vitro anticancer evaluation, kinase inhibitory effects, and pharmacokinetic profile of new 1,3,4-triarylpyrazole derivatives possessing terminal sulfonamide moiety
title Design, synthesis, in vitro anticancer evaluation, kinase inhibitory effects, and pharmacokinetic profile of new 1,3,4-triarylpyrazole derivatives possessing terminal sulfonamide moiety
title_full Design, synthesis, in vitro anticancer evaluation, kinase inhibitory effects, and pharmacokinetic profile of new 1,3,4-triarylpyrazole derivatives possessing terminal sulfonamide moiety
title_fullStr Design, synthesis, in vitro anticancer evaluation, kinase inhibitory effects, and pharmacokinetic profile of new 1,3,4-triarylpyrazole derivatives possessing terminal sulfonamide moiety
title_full_unstemmed Design, synthesis, in vitro anticancer evaluation, kinase inhibitory effects, and pharmacokinetic profile of new 1,3,4-triarylpyrazole derivatives possessing terminal sulfonamide moiety
title_short Design, synthesis, in vitro anticancer evaluation, kinase inhibitory effects, and pharmacokinetic profile of new 1,3,4-triarylpyrazole derivatives possessing terminal sulfonamide moiety
title_sort design, synthesis, in vitro anticancer evaluation, kinase inhibitory effects, and pharmacokinetic profile of new 1,3,4-triarylpyrazole derivatives possessing terminal sulfonamide moiety
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211260/
https://www.ncbi.nlm.nih.gov/pubmed/30362383
http://dx.doi.org/10.1080/14756366.2018.1530225
work_keys_str_mv AT abdelmaksoudmohammeds designsynthesisinvitroanticancerevaluationkinaseinhibitoryeffectsandpharmacokineticprofileofnew134triarylpyrazolederivativespossessingterminalsulfonamidemoiety
AT elgamalmohammedi designsynthesisinvitroanticancerevaluationkinaseinhibitoryeffectsandpharmacokineticprofileofnew134triarylpyrazolederivativespossessingterminalsulfonamidemoiety
AT gamaleldinmahmoudm designsynthesisinvitroanticancerevaluationkinaseinhibitoryeffectsandpharmacokineticprofileofnew134triarylpyrazolederivativespossessingterminalsulfonamidemoiety
AT ohchanghyun designsynthesisinvitroanticancerevaluationkinaseinhibitoryeffectsandpharmacokineticprofileofnew134triarylpyrazolederivativespossessingterminalsulfonamidemoiety